Total
0
Shares
Small Pharma - CEO, Peter Rands.
CEO, Peter Rands.
Source: Small Pharma.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Small Pharma (DMT) has been granted a European patent, strengthening its ketamine-based patent portfolio
  • The patent grants certain protections for a range of oral dosage forms of 2R,6R-hydroxynorketamine-based compounds
  • This includes the company’s preclinical candidate, SPL801B, for the treatment of depressive disorders
  • Early preclinical studies of SPL801B have shown signs of potential antidepressant properties without ketamine’s psychoactive effects
  • Small Pharma is a neuropharmaceutical company specialized in IP-led development of treatments for mental health conditions with a focus on depression
  • Small Pharma (DMT) is unchanged trading at $0.69 per share

Small Pharma (DMT) has been granted a European patent, strengthening its ketamine-based patent portfolio.

The company received European patent grant number EP 3 463 323 as acceptance for its patent application No. 17 728640.8.

The patent grants certain protections for a range of oral dosage forms of 2R,6R-hydroxynorketamine (6-HNK), an active ketamine metabolite.

It also provides protection for a solid oral dosage form of the company’s preclinical candidate, SPL801B, in combination with a serotonin modulator, for the treatment of depressive disorders.

Early preclinical studies of SPL801B have shown signs of potential antidepressant properties without the psychoactive effects typically associated with ketamine.

Peter Rands, Small Pharma’s CEO, stated,

“We continue to experience rapid maturation both in our corporate profile and the progression of our pipeline of therapeutic candidates. Securing the patent rights to SPL801B, our preclinical ketamine-based candidate for the treatment of depression, allows us to securely investigate its commercial potential.

This is the third patent to be granted in our growing IP portfolio, which protects the company’s rights to innovate and develop novel treatment candidates for mental health conditions.”

Small Pharma is a neuropharmaceutical company specialized in IP-led development of treatments for mental health conditions with a focus on depression. 

Small Pharma (DMT) is unchanged trading at $0.69 per share as of 12:39 pm ET.

More From The Market Herald
BioMark Diagnostics - Founder and CEO, Rashid Bux

" BioMark (CSE:BUX) to collaborate with AstraZeneca and Pfizer Canada to improve early detection of lung cancer

BioMark Diagnostics (BUX) will participate in a research project that aims to enhance the efficiency of lung cancer screening programs.

" Algernon Pharmaceuticals (CSE:AGN) welcomes new CFO

Algernon Pharmaceuticals (AGN) has appointed Mr. James Kinley as the Chief Financial Officer (CFO), effective December 1, 2021.

" Beyond Medical Technologies (CSE:DOCT) ramps up mask manufacturing in response to new South African variant

Beyond Medical Technologies (DOCT) subsidiary Micron Technologies has been manufacturing medical masks in British Columbia since August 2020.

" Sun Life Financial (TSX:SLF) partners with CloudMD (TSXV:DOC)

Sun Life (SLF) has partnered with CloudMD (DOC) to add its Mental Health Coach solution to group benefits plans.